CN115768432A - 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 - Google Patents

使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 Download PDF

Info

Publication number
CN115768432A
CN115768432A CN202180039610.0A CN202180039610A CN115768432A CN 115768432 A CN115768432 A CN 115768432A CN 202180039610 A CN202180039610 A CN 202180039610A CN 115768432 A CN115768432 A CN 115768432A
Authority
CN
China
Prior art keywords
effective amount
days
administration
compound
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180039610.0A
Other languages
English (en)
Chinese (zh)
Inventor
M·J·苏托
R·博海科
郑斗瑛
李振洙
赵显龙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pinot Bio Co ltd
Southern Research Institute
Original Assignee
Pinot Bio Co ltd
Southern Research Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pinot Bio Co ltd, Southern Research Institute filed Critical Pinot Bio Co ltd
Publication of CN115768432A publication Critical patent/CN115768432A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202180039610.0A 2020-04-23 2021-04-22 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途 Pending CN115768432A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063014346P 2020-04-23 2020-04-23
US63/014,346 2020-04-23
PCT/US2021/028726 WO2021216936A1 (en) 2020-04-23 2021-04-22 Composition for treating blood cancer using 4'-thio-5-aza-2'-deoxycytidine and uses thereof

Publications (1)

Publication Number Publication Date
CN115768432A true CN115768432A (zh) 2023-03-07

Family

ID=78221459

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180039610.0A Pending CN115768432A (zh) 2020-04-23 2021-04-22 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途

Country Status (8)

Country Link
US (2) US12208112B2 (https=)
EP (1) EP4138843A4 (https=)
JP (1) JP2023524912A (https=)
KR (1) KR20230004768A (https=)
CN (1) CN115768432A (https=)
AU (1) AU2021260964A1 (https=)
CA (1) CA3176543A1 (https=)
WO (1) WO2021216936A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187391A (zh) * 2023-09-15 2023-12-08 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
KR20240108406A (ko) 2021-10-19 2024-07-09 아키라바이오, 인크. 2'-데옥시시티딘 유사체를 포함하는 조성물 및 겸상 적혈구 질환, 지중해빈혈, 및 암의 치료를 위한 그의 용도
WO2024191252A1 (ko) * 2023-03-14 2024-09-19 주식회사 피노바이오 골수에 작용하는 5-아자-4'-티오-2'-데옥시사이티딘의 최고 혈중농도를 정교하게 제어가능한 경구용 제형
WO2025100762A1 (ko) * 2023-11-08 2025-05-15 한국생명공학연구원 4'-티오-5-아자-2'-디옥시사이티딘을 포함하는 간질환의 개선, 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6020322A (en) 1993-11-09 2000-02-01 Pro-Neuron, Inc. Acyl deoxyribonucleoside derivatives and uses thereof
US5591722A (en) 1989-09-15 1997-01-07 Southern Research Institute 2'-deoxy-4'-thioribonucleosides and their antiviral activity
ES2402799T3 (es) 1998-07-23 2013-05-09 Southern Research Institute Prepreparación de compuestos de tioarabinofuranosilo y utilización de los mismos
WO2004018494A1 (ja) 2002-08-22 2004-03-04 Geneticlab Co., Ltd. ４’−チオヌクレオチド
US20060014949A1 (en) 2004-07-13 2006-01-19 Supergen Inc. Compositions and formulations of decitabine polymorphs and methods of use thereof
KR101125932B1 (ko) 2006-12-06 2012-03-22 아이디유엔 파마슈티칼즈, 인코포레이티드 (3ｓ)-3-［ｎ-(ｎ'-(2-ｔｅｒｔ-부틸페닐)옥사밀)알라니닐］아미노-5-(2',3',5',6'-테트라플루오로페녹시)-4-옥소펜탄산의 결정 형태
EP3782612B1 (en) 2008-05-15 2023-11-08 Celgene Corporation Oral formulations of cytidine analogs and methods of use thereof
WO2011109383A1 (en) 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy -4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
WO2011109012A1 (en) * 2010-03-02 2011-09-09 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents
BR112016028641A2 (pt) * 2014-07-14 2017-08-22 Gilead Sciences Inc ?método para tratar câncer?
TWI678373B (zh) 2014-10-31 2019-12-01 日商富士軟片股份有限公司 硫代核苷衍生物或其鹽及醫藥組合物
US10662214B2 (en) 2015-04-03 2020-05-26 Sichuan Keiun-Biotech Biopharmaceutical Co., Ltd. Compound of 4′-thionucleoside, as well as preparation method therefor, pharmaceutical composition thereof and application thereof
US20160312261A1 (en) 2015-04-24 2016-10-27 Plasmia Biotech, S.L. Enzymatic production of cytosinic nucleoside analogues
HK1252245A1 (zh) 2015-05-27 2019-05-24 Idenix Pharmaceuticals Llc 用於治疗癌症的核苷酸
EP3207932A1 (en) * 2016-02-19 2017-08-23 Universität Stuttgart Dna methyltransferase inhibitors for rett syndrome therapy
US20190240210A1 (en) * 2016-10-17 2019-08-08 Daiichi Sankyo Company, Limited Treatment Method by Combined Use of MDM2 Inhibitor and DNA Methyltransferase Inhibitor
JP7425734B2 (ja) 2018-02-01 2024-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－デオキシヌクレオシドを製造するための立体選択的合成およびプロセス
CA3097003A1 (en) * 2018-04-19 2019-10-24 Southern Research Institute 4'-thio-nucleotide and -nucleoside prodrugs for the treatment of cancer
JP7520822B2 (ja) 2018-09-25 2024-07-23 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ ２’－ハロゲン化－４’－チオ－２’－デオキシ－５－アザシチジンアナログおよびその使用

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110218170A1 (en) * 2010-03-02 2011-09-08 Southern Research Institute Use of 2'-deoxy-4'-thiocytidine and its analogues as dna hypomethylating anticancer agents

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117187391A (zh) * 2023-09-15 2023-12-08 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用
CN117187391B (zh) * 2023-09-15 2025-03-18 中国医学科学院北京协和医院 普卡霉素在垂体促肾上腺皮质激素腺瘤中的应用

Also Published As

Publication number Publication date
WO2021216936A1 (en) 2021-10-28
US20250082662A1 (en) 2025-03-13
KR20230004768A (ko) 2023-01-06
AU2021260964A1 (en) 2022-12-01
US12208112B2 (en) 2025-01-28
JP2023524912A (ja) 2023-06-13
EP4138843A1 (en) 2023-03-01
US20210330689A1 (en) 2021-10-28
EP4138843A4 (en) 2024-07-10
CA3176543A1 (en) 2021-10-28

Similar Documents

Publication Publication Date Title
CN115768432A (zh) 使用4’-硫代-5-氮杂-2’-脱氧胞苷来治疗血癌的组合物及其用途
Hopper et al. Ivermectin toxicity in 17 collies
EP3148545B1 (en) Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids
EP3662909A1 (en) Gamma secretase modulators for the treatment of immune system dysfunction
EP0759750A1 (en) Compositions for treatment of chronic inflammatory diseases
US20140274937A1 (en) Methods of treating hematologic cancers
Anderson et al. Fludarabine: a review of its use in non-Hodgkin’s lymphoma
CN1095366C (zh) N－乙酰－d－氨基葡萄糖在制备治疗肠道疾病药物中的应用
EP1951233B1 (en) Pirfenidone/toll-like receptor (tlr) agonist compositions and methods for using them to stimulate production of granulocyte colonizing stimulating factor (g-csf)
EP2997969A1 (en) Treatment agent and treatment method for intestinal examination or surgery
Patel et al. Safety level of Levofloxacin following repeated oral adminstration in White Leg Horn layer birds
Kano et al. Systemic treatment of sterile panniculitis with tacolimus and prednisolone in dogs
WO1994005287A1 (en) Prevention or treatment of sepsis with dantrolene or azumolene
Sadariya et al. Safety of Moxifloxacin following repeated intramuscular administration in Wistar rats
EP2392341A1 (en) Compositions for use in treating myelodysplastic syndrome
Kanaeva et al. Clinical and Experimental Substantiation of The Use of Macrolide Antibiotic in Gastrointestinal and Respiratory Diseases
EP0655918A1 (en) Treatment of cancer with azt and alkylating or intercalating agents
EP0624368A2 (en) Use of a composition for stimulating the synthesis of glutathione in the manufacture of a medicament for the treatment of acquired immune deficiency syndrome
JP2021530512A (ja) 体重増加を抑制するためのロイテリサイクリンまたはラクトバチルス・ロイテリ
Jiménez-Galán et al. 4CPS-311 Real world toxicity and management of chimeric antigen receptor T cell therapies targeting CD19 in patients with haematological malignancies
Phosphate et al. Pr FLUDARABINE PHOSPHATE INJECTION, USP
Southgate Sarafin®, a novel quinolone for bacterial disease in salmon
CZ20033145A3 (cs) Identifikace parazitických plísní v organismu a jejich léčení
HK40031928A (en) Gamma secretase modulators for the treatment of immune system dysfunction
Bifano et al. 884 CALCIUM-INDUCED ECHINOCYTOSIS (E) IN HUMAN RED BLOOD CELLS FROM NEONATES (N) AND ADULTS (A)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination